ERBB2 and heart failure: Additionally, previous studies have shown that cancer survivors had a substantially higher risk of hypertension and heart failure, which might be attributable to the exposure to cardiotoxic chemotherapy agents in cancer patients, such as anthracyclines,5-fluorouracil, paclitaxel, erythritol-elastic oncogene B-2 (ErbB2) and other types of chemotherapy agents, which cause injury to endothelial cells and cardiomyocytes, eventually leading to the development of hypertension, heart failure and even cardiac death [42, 43].